Zosuquidar (trihydrochloride)

Zosuquidar (LY335979) trihydrochloride is a P-glycoprotein (P-gp) inhibitor (Ki=59 nM) . Zosuquidar trihydrochloride shows anti-tumor activities, and can be used in acute myelogenous leukemia (AML) research[1][2][3].

Product Specifications

CAS Number

[167465-36-3]

Product Name Alternative

RS 33295-198 trihydrochloride; LY-335979 trihydrochloride

UNSPSC

12352005

Hazard Statement

H315, H319, H335

Target

P-glycoprotein

Type

Reference compound

Related Pathways

Membrane Transporter/Ion Channel

Applications

Cancer-programmed cell death

Field of Research

Cancer

Assay Protocol

https://www.medchemexpress.com/Zosuquidar-trihydrochloride.html

Purity

99.50

Solubility

DMSO : 1 mg/mL (ultrasonic) |H2O : 5 mg/mL (ultrasonic)

Smiles

FC1([C@H]2[C@@H]1C3=C([C@@H](C4=CC=CC=C42)N5CCN(CC5)C[C@H](COC6=C7C=CC=NC7=CC=C6)O)C=CC=C3)F.Cl.Cl.Cl

Molecular Formula

C32H34Cl3F2N3O2

Molecular Weight

636.99

Precautions

H315, H319, H335

References & Citations

[1]A H Dantzig, et al. Reversal of P-glycoprotein-mediated multidrug resistance by a potent cyclopropyldibenzosuberane modulator, LY335979. Cancer Res. 1996 Sep 15;56 (18) :4171-9.|[2]Ruoping Tang, et al. Zosuquidar restores drug sensitivity in P-glycoprotein expressing acute myeloid leukemia (AML) . BMC Cancer. 2008 Feb 13;8:51.|[3]Larry D Cripe, et al. Zosuquidar, a novel modulator of P-glycoprotein, does not improve the outcome of older patients with newly diagnosed acute myeloid leukemia: a randomized, placebo-controlled trial of the Eastern Cooperative Oncology Group 3999. Blood. 2010 Nov 18;116 (20) :4077-85.